Anthropic’s $1 billion investment in embedded AI oversight and implications for Australia’s healthcare leaders.
Anthropic’s founder is obsessed with AI’s duality. Will it lead to a Terminator-style Judgement Day or the work-free, money-free, future Elon Musk predicts?
So it wasn’t surprising to see that Anthropic (the developer of Claude) is a first mover on embedded AI oversight. But it’s the scale of their investment that shows how seriously they’re taking it.
What does $1 billion of embedded AI oversight buy?
The details are still being worked out but at its core Anthropic will give a team of embedded third-party evaluators employee-like access to test its models. Their job will be to check adherence to safety practices and commitments. Report incidents. Identify blind spots. The goal is to ensure Anthropic’s AI advancements don’t outrun their ability to understand and control it.
What should embedded AI oversight look like in Australian healthcare?
We have seen rapid adoption of AI technology in the sector – and for good reason. Take ambient scribes. They promise to tackle two stubborn problems at once: clinician burnout and the pressure to improve productivity. Less time on paperwork. More time and energy for patients.
It’s easy to see why we’re seeing so many AI pilots (see Calvary Health Care, Monash Health and Northern Health) and why the number of GPs using AI scribes has doubled in little over a year.
While there’s been progress on high-level principles and guidance, many organisations still lack the practical arrangements needed to manage AI’s risks. There is progress here. A recent paper co-authored by Farah Magrabi sets out a practical framework for AI governance in healthcare organisations.
But there’s a danger in just focusing on risks. In its March 2025 report, the Peterson Health Technology Institute’s (PHTI) AI Taskforce highlighted a critical blind spot in ambient scribe pilots: US healthcare executives don’t have the data to know whether AI is delivering on its promised benefits.
Are clinicians less burnt out and more likely to stay? Are patients having a better experience? Is time saved translating into higher productivity or better care? And do those gains justify the costs?
Without answers to these questions, executives won’t have the evidence they need to decide whether to scale.
The PHTI Taskforce warns without robust measurement frameworks in place, the rapid adoption of AI technology could actually increase the overall cost of healthcare.
That’s why embedded AI oversight needs a dual focus – safety and benefits. It needs to give healthcare leaders the evidence to decide what to expand, what to change and when to stop.
So what would that dual focus look like in practice?
We’re facilitating a series of roundtables to help design an embedded AI oversight model for Australian healthcare.
Who should attend
Leaders of Australian healthcare organisations that have started an AI pilot and need to decide whether to scale it.
What we’ll discuss
- What does your pilot need to demonstrate before you commit to wider use?
- Do you have the measures and data to assess benefits, costs and risks?
- What ongoing oversight needs to be in place before you scale?
We’ll present some of the latest research on AI’s risks and benefits, hear participants’ experiences and explore how embedded oversight could support decisions about scaling.
If you’re weighing up whether to scale an AI pilot, register for a roundtable or pop me an email.
Brendan Roche is a partner at HealthConsult, a specialist management consultancy serving the health, aged care and disability sectors.